Price
No data yet.
Social Signal Score
Revenue
$105.86M+8886.84%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Lisa Graver
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Employees
- 1,279
- Beta
- 0.18
- Country
- LU
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- -1.30
Financials
Revenue
$105.86M+8886.8%Net Income
$1.03MEBITDA
$52.08MFree Cash Flow
$-106.62MEPS (diluted)
$0.00Shares Outstanding (diluted)
330.28M+956.9%Operating Expenses
$50.18MCash & Debt
$63.83MReturn of Capital
$0.00Revenue by Segment (annual)
$12.20BQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $586.32M | $27.92M | $0.10 |
| 2024 | $489.68M | $-231.86M | $-0.87 |
| 2023 | $91.43M | $-551.73M | $-2.43 |
| 2022 | $83.03M | $-513.58M | $-2.60 |
| 2021 | $36.77M | $-101.50M | $-3.25 |
| 2020 | $66.62M | $-170.04M | $-5.44 |
| 2019 | $31.92M | $-209.88M | $-0.86 |
Valuation
Project earnings forward and see what return today's price implies.
EPS was negative in at least one boundary year, so a compound growth rate can't be computed from it. Set your own assumption.
- EPS in 5 years
- $0.15
- Implied price
- $7.49
- Return from $3.99
- 13.4% a year
To earn 15.0% a year on these assumptions you'd need to buy at $3.73 — -6.6% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 35 | 43 | 51 | 59 | 67 |
|---|---|---|---|---|---|
| -2.0% | -4.5% | -0.5% | 2.9% | 6.0% | 8.7% |
| 3.0% | 0.3% | 4.6% | 8.2% | 11.4% | 14.3% |
| 8.0% | 5.2% | 9.6% | 13.4% | 16.8% | 19.8% |
| 13.0% | 10.1% | 14.7% | 18.7% | 22.2% | 25.3% |
| 18.0% | 14.9% | 19.8% | 23.9% | 27.6% | 30.9% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
102Social Signal Score
Mentions (3)
- Newszacks.com·4h ago·Neutral
Alvotech (ALVO) Reports Q2 Loss, Beats Revenue Estimates Alvotech (ALVO) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.06. This compares to earnings of $0.14 per share a year ago.
View source ↗ - Newsglobenewswire.com·6h ago·Neutral
Alvotech Announces Financial Results for the First Half of 2026 and Provides a Business Update REYKJAVIK, Iceland, Aug. 19, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO; ALVO-SDB) ("Alvotech" or the "Company"), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced financial results for the first half of 2026 and provided a business update.
View source ↗ - Newsglobenewswire.com·6h ago·Neutral
Alvotech Announces Financial Results for the First Half of 2026 and Provides a Business Update REYKJAVIK, ICELAND (August 19, 2026) — Alvotech (NASDAQ: ALVO; ALVO-SDB) (“Alvotech” or the “Company”), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced financial results for the first half of 2026 and provided a business update.
View source ↗
Earnings
Wed, Nov 11(in 3 months)
Consensus estimate $-0.04 per share
Typical surprise -1.9% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Aug 19$-0.11 vs $-0.05miss
- Wed, May 6$-0.09 vs $-0.07miss
- Wed, Mar 18$-0.37 vs $-0.01miss
- Wed, Nov 12$-0.02 vs $-0.03beat
- Wed, Aug 13$0.14 vs $-0.05beat
- Wed, May 7$0.35 vs $-0.08beat
Estimates and results for ALVO via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.